Cas:13956-52-0 (4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol manufacturer & supplier

We serve Chemical Name:(4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol CAS:13956-52-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol

Chemical Name:(4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol
CAS.NO:13956-52-0
Synonyms:(3S,4S,4aR,6aS,9aR,11S,13aR,13bS,15aS,15bR)-4-(Hydroxymethyl)-4,6a,10,10,13a,15b-hexamethyl-2,3,4,4a,5,6,6a,7,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-naphtho[2′,1′:4,5]cyclohepta[1,2-a]naphthalene-3,11-diol;1H-Cyclohepta[1,2-a:5,4-a’]dinaphthalene-3,11-diol, 2,3,4,4a,5,6,6a,7,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-eicosahydro-4-(hydroxymethyl)-4,6a,10,10,13a,15b-hexamethyl-, (3S,4S,4aR,6aS,9aR,11S,13aR,13bS,15aS,15bR)-
Molecular Formula:C30H50O3
Molecular Weight:458.716
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:566.1±50.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.562
PSA:60.69000
Exact Mass:458.376007
LogP:7.45

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (3S,4S,4aR,6aS,9aR,11S,13aR,13bS,15aS,15bR)-4-(Hydroxymethyl)-4,6a,10,10,13a,15b-hexamethyl-2,3,4,4a,5,6,6a,7,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-naphtho[2′,1′:4,5]cyclohepta[1,2-a]naphthalene-3,11-diol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Cyclohepta[1,2-a:5,4-a’]dinaphthalene-3,11-diol, 2,3,4,4a,5,6,6a,7,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-eicosahydro-4-(hydroxymethyl)-4,6a,10,10,13a,15b-hexamethyl-, (3S,4S,4aR,6aS,9aR,11S,13aR,13bS,15aS,15bR)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3S,4S,4aR,6aS,9aR,11S,13aR,13bS,15aS,15bR)-4-(Hydroxymethyl)-4,6a,10,10,13a,15b-hexamethyl-2,3,4,4a,5,6,6a,7,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-naphtho[2′,1′:4,5]cyclohepta[1,2-a]naphthalene-3,11-diol Use and application,(3S,4S,4aR,6aS,9aR,11S,13aR,13bS,15aS,15bR)-4-(Hydroxymethyl)-4,6a,10,10,13a,15b-hexamethyl-2,3,4,4a,5,6,6a,7,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-naphtho[2′,1′:4,5]cyclohepta[1,2-a]naphthalene-3,11-diol technical grade,usp/ep/jp grade.


Related News: Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more. (4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol manufacturer Any South Korean citizen returning home who has been in Hubei Province within the past two weeks will be subject to 14 days of self-quarantine and monitoring, the government said. (4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol supplier Amanpour is based in London, and said she feels fortunate to have health insurance through work and incredible doctors who are treating me in a country underpinned by, of course, the brilliant NHS [National Health Service],” CNN reported.
“I want to applaud Christiane Amanpour for her candor, bravery and always working towards the greater good,” he said in a statement. “As a cancer survivor, I too encourage people to listen to their bodies and get all early cancer screenings available to them. (4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol vendor Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more. (4S)-C(14a)-Homo-27-norgammacer-14-ene-3β,21α,24-triol factory Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.